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ABSTRACT
OBJECTIVES The aim of this study was to examine the frequency and clinical impact of different cessation
patterns of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting stents among
patients with and those without diabetes mellitus (DM).
BACKGROUND Early DAPT suspension after percutaneous coronary intervention increases the risk for major adverse
cardiac events. However, temporal variability in risk and relation to DAPT cessation patterns among patients with DM
remain unclear.
METHODS Using data from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients)
registry, 1,430 patients with DM (34%) and 2,777 without DM (66%) treated with drug-eluting stents were identiﬁed.
DAPT cessation modes were classiﬁed as temporary interruption (<14 days), disruption because of bleeding or poor
compliance, and physician-recommended discontinuation.
RESULTS During 2-year follow-up, DM was associated with an increased risk for thrombotic events but a similar risk
for bleeding. The cumulative incidence of DAPT cessation was signiﬁcantly lower in patients with versus those without
DM (50.1% vs. 55.4%; p < 0.01), driven largely by less frequent physician-guided discontinuation beyond 1 year. In
contrast, 2-year rates of interruption and disruption were similar between groups. When DAPT was interrupted or
discontinued under physician guidance, the risk for major adverse cardiac events was unchanged compared with
patients with DM on uninterrupted DAPT. Conversely, when DAPT was disrupted, the risk for major adverse cardiac
events increased compared with uninterrupted DAPT, regardless of diabetic status, with no evidence of statistical
interaction.
CONCLUSIONS DAPT cessation patterns vary according to diabetic status, with less frequent physician-guided
discontinuation among patients with DM. The presence of DM does not emerge as a modiﬁer of cardiovascular risk after
DAPT cessation. (J Am Coll Cardiol Intv 2017;10:645–54) © 2017 by the American College of Cardiology Foundation.
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D iabetes mellitus (DM) is a majorindependent risk factor for cardio-vascular diseases, including myo-
cardial infarction (MI), heart failure, and
stroke. After a successful percutaneous
coronary intervention (PCI), the rate of
cardiovascular outcomes in patients with
DM is signiﬁcantly higher than in the general
population despite strict glycemic control
and treatment of concomitant modiﬁable
risk factors such as hypertension and dyslipi-
demia (1–4). Although the introduction of
second-generation drug eluting stents (DES)
has reduced the rate of target lesion failure
and repeat revascularization in patients
with DM, incidence continues to be higher
than in patients without DM (5,6).
Current clinical practice guidelines on the man-
agement of patients undergoing PCI recommend 6- to
12-month dual antiplatelet therapy (DAPT) with
aspirin and a P2Y12 inhibitor following DES implanta-
tion unless patients are at high risk for bleeding (7).
There is no speciﬁc indication for DAPT duration in
patients with DM. Therefore, the most appropriate
DAPT regimen for patients with DM remains a subject
of debate. Recent observational studies have sug-
gested that short-term DAPT could be safe and effec-
tive in patients with DM with either stable coronary
artery disease or low-risk acute coronary syndromes
(ACS) after the implantation of second-generation
DES (8–10). However, these results might not apply
to high-risk patients with DM and ACS or to patients
receiving bare-metal stents or ﬁrst-generation DES.
Cessation of DAPT treatment after PCI in the gen-
eral population is critical, because it increases the risk
for adverse clinical outcomes. In particular, results
from the observational PARIS (Patterns of Non-
Adherence to Anti-Platelet Regimens in Stented
Patients) registry have shown that in an all-comers
population undergoing PCI, the effect of DAPT cessa-
tion on cardiovascular risk depends not only on the
time of cessation but also on the underlying cessation
mode (11). The effect of early DAPT cessation in real-
world patients with DM is unknown. In this study
we used data from the PARIS registry to investigate
modes of DAPT cessation in patients with DM up to
2 years after PCI with DES compared with patients
without DM. Furthermore, we evaluated the effects
of different DAPT cessation modes on the risk for
cardiovascular adverse events.
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
CI = conﬁdence interval
DAPT = dual-antiplatelet
therapy
DES = drug-eluting stent(s)
DM = diabetes mellitus
HR = hazard ratio
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
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METHODS
STUDY POPULATION. PARIS was a multicenter pro-
spective observational study that enrolled patients
who were discharged on DAPT after successful PCI
with implantation of at least 1 stent between July
2009 and December 2010. The design and results
of this study have been previously published (11).
Exclusions from the study included PCI for stent
thrombosis and participation in an investigational
drug or device trial. Patients were followed up via
telephone by trained research coordinators at each
participating site 1, 6, 12, 24, and 48 months after
index PCI to assess DAPT compliance and record any
major adverse events. Any relevant source docu-
ments were obtained for patients reporting any
adverse events. An external clinical events committee
adjudicated all events. Among the 5,031 patients
enrolled in PARIS, we excluded patients who under-
went PCI with 1 or more bare-metal stents. The
remaining 4,207 patients constitute the population
for this subanalysis and have been divided according
to diabetic status. Diabetic status was determined by
the presence of a history of DM on the patient’s
medical record and/or the prescription of glucose-
lowering medications. Baseline characteristics, med-
ical treatment, and incidence of DAPT cessation were
compared between patients with and those without
DM. In addition, we assessed the frequency of any
DAPT cessation mode in the 2 groups, patients with
and those without DM, and compared the risk for
clinical outcomes with any DAPT cessation with
uninterrupted DAPT therapy.
STUDY DEFINITIONS. Adverse events were classiﬁed
as in the PARIS study (11). In brief, the primary major
adverse cardiac event (MACE) was deﬁned as a com-
posite of cardiac death, probable or deﬁnite stent
thrombosis, spontaneous MI, and clinically indicated
target lesion revascularization. A more restrictive
composite endpoint was also used (MACE 2) that
excluded target lesion revascularization. Sponta-
neous MI was deﬁned as elevated cardiac biomarkers
in the presence of clinical or electrocardiographic
changes consistent with cardiac ischemia. Stent
thrombosis was adjudicated according to the Aca-
demic Research Consortium deﬁnition (12,13). Target
lesion revascularization comprised both percuta-
neous and surgical reintervention on the target
lesion. A bleeding event was deﬁned as one that
met the criteria for Bleeding Academic Research
Consortium type 3 or greater. All bleeding events
were also adjudicated with the TIMI (Thrombolysis
In Myocardial Infarction) and ACUITY (Acuity Cathe-
terization and Urgent Intervention Triage Strategy)
deﬁnitions as a supplement to the Bleeding Academic
Research Consortium deﬁnition (13). All adjudications
were performed by an outside committee. As deﬁned
in PARIS, modes of DAPT cessation were identiﬁed
and classiﬁed as follows: physician-guided cessation
because of the lack of an indication to continue DAPT
(discontinuation), temporary (#14 days) cessation of
FIGURE 1 Study Flowchart
DAPT ¼ dual-antiplatelet therapy; DES ¼ drug-eluting stent(s); DM ¼ diabetes mellitus; PCI ¼ percutaneous coronary intervention.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 0 , N O . 7 , 2 0 1 7 Faggioni et al.
A P R I L 1 0 , 2 0 1 7 : 6 4 5 – 5 4 DAPT Cessation in Patients With Diabetes After PCI
647
DAPT because of the need for an invasive procedure
(interruption), and DAPT cessation because of a lack
of adherence or a bleeding event (disruption).
Importantly, DAPT cessation events were not mutu-
ally exclusive, and patients could experience more
than 1 DAPT cessation mode (discontinuation, inter-
ruption, or disruption) during the investigation time.
In that case, the DAPT cessation variable was adju-
dicated according to the following hierarchical order:
disruption had priority over interruption, which in
turn had priority over recommended discontinuation.
Additionally, DAPT cessation longer than 30 days did
not preclude the reinclusion of patients subsequently
resuming DAPT.
STATISTICAL ANALYSIS. Categorical variables are
expressed as percentages and were compared, be-
tween patients with and those without DM, using
chi-square tests. Continuous variables are expressed
as mean  SD and were compared using Student t
test. Kaplan-Meier estimates represent time to event
incidences and were compared using log-rank tests.
Risk for cardiovascular outcomes according to DAPT
cessation mode in patients with and those without
DM was calculated using an extended Cox regression,
a ﬂexible modeling approach that allows departures
from proportional hazards with covariates that either
interact with or vary by time (14,15). DAPT cessation
entered the model as a time-updated categorical
variable as previously described (11). Other covariates
included in the model were age, sex, body mass in-
dex, smoking status, clinical presentation, region
(United States vs. Europe), education level, stent
type (second vs. ﬁrst generation), prior MI, prior
coronary artery bypass graft surgery, prior PCI,
thrombotic lesion, bifurcation lesion, multivessel PCI
(1-vessel vs. 2- or 3-vessel PCI). Hazard ratios (HRs)
are expressed using uninterrupted DAPT as a
comparator within each study group, patients with
and those without DM. A test for interaction was
performed between diabetic status and DAPT cessa-
tion pattern. Stata version 12.1 (StataCorp, College
Station, Texas) and SAS version 9.3 (SAS Institute,
Cary, North Carolina) were used for the statistical
analyses.
TABLE 1 Baseline Characteristics
No Diabetes
(n ¼ 2,777,
66.0%)
Diabetes
(n ¼ 1,430,
34.0%) p Value
Male 2,125 (76.5) 1,010 (70.6) <0.0001
Age, yrs 63.4  11.5 64.5  10.1 <0.01
BMI, kg/m2 28.51  5.17 30.85  5.93 <0.0001
Dyslipidemia 2,052 (73.9) 1,216 (85.0) <0.0001
Hypertension 2,132 (76.8) 1,280 (89.5) <0.0001
Family history of CAD 882 (31.8) 479 (33.5) 0.25
Ever smoker 1,458 (52.5) 712 (49.8) 0.01
Education level <0.0001
Advanced university degree 321 (11.6) 106 (7.4)
Tertiary university degree 791 (28.5) 400 (28.0)
Secondary school 1,340 (48.3) 714 (49.9)
Less than secondary school 264 (9.5) 180 (12.6)
Ischemic history
Previous CAD 1,360 (49.0) 825 (57.7) <0.0001
Previous MI 651 (23.4) 393 (27.5) <0.05
Previous PCI 1,032 (37.2) 629 (44.0) <0.0001
Previous CABG 359 (12.9) 244 (17.1) <0.001
Stroke/CVA 77 (2.8) 69 (4.8) <0.001
PVD 198 (7.1) 136 (9.5) <0.01
Cardiac status at admission
Silent ischemia 288 (10.4) 163 (11.4) 0.30
Stable angina 1,365 (49.2) 806 (56.4) <0.0001
Acute coronary syndrome 1,124 (40.5) 461 (32.2) <0.0001
Values are n (%) or mean  SD.
BMI¼ body mass index; CABG¼ coronary artery bypass grafting; CAD¼ coronary artery disease
including myocardial infarction, PCI, and CABG; CVA ¼ cerebrovascular accident; MI ¼ myocardial
infarction; PCI ¼ percutaneous coronary intervention; PVD ¼ peripheral vascular disease; TIA ¼
transient ischemic attack.
TABLE 2 Procedural Characteristics
No
Diabetes
(n ¼ 2,777,
66.0%)
Diabetes
(n ¼ 1,430,
34.0%) p Value
PCI vessel
Left main 93 (3.3) 49 (3.4) 0.89
LAD 1,345 (48.4) 677 (47.3) 0.50
Proximal LAD 687 (24.7) 311 (21.7) 0.03
LCx 877 (31.6) 446 (31.2) 0.80
RCA 928 (33.4) 490 (34.3) 0.58
Number of vessels treated 0.80
1 2,342 (84.3) 1,211 (84.7)
2 404 (14.5) 206 (14.4)
3 31 (1.1) 13 (0.9)
Bifurcation lesion 372 (13.4) 153 (10.7) 0.01
Chronic total occlusion 114 (4.1) 58 (4.1) 0.90
Thrombotic lesion 223 (8.0) 57 (4.0) <0.0001
Stent type 0.20
DES, ﬁrst-generation 432 (15.6) 242 (16.9)
DES, second-generation 2,345 (84.4) 1,188 (83.1)
Number of stents implanted 0.40
1 1,483 (53.4) 736 (51.5)
2 797 (28.7) 437 (30.6)
>2 497 (17.9) 257 (18.0)
Total stent length 0.80
#20 mm 978 (35.2) 498 (34.8)
>20 mm 1,799 (64.8) 932 (65.2)
GP inhibitor 353 (12.7) 161 (11.3) 0.20
Values are n (%).
DES ¼ drug-eluting stent(s); GP ¼ glycoprotein; LAD ¼ left anterior descending
coronary artery; LCx ¼ left circumﬂex coronary artery; PCI ¼ percutaneous
coronary intervention; RCA ¼ right coronary artery.
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RESULTS
BASELINE CHARACTERISTICS. Among the 5,031
patients enrolled in the PARIS registry, 4,207 received
at least 1 DES during their index PCI and were
included in this subanalysis (see study ﬂowchart in
Figure 1). Of this cohort, 1,430 patients (34.0%) had
DM. Table 1 shows the baseline characteristics of the
study population according to diabetic status. In
brief, patients with DM were more often male (70%)
and older (63.4  11.5 years vs. 64.5  10.1 years;
p < 0.01) and had a higher frequency of cardiovas-
cular risk factors such as hypertension and hyper-
cholesterolemia compared with those without DM.
However, they were less likely to be current or past
smokers. Diabetic status was associated with a history
of cardiovascular diseases, including previous MI,
previous PCI with stent implantation, coronary artery
bypass graft surgery, stroke, and peripheral vessel
disease. Upon admission, patients with DM more
often presented with silent ischemia or with stable
coronary disease. On the contrary, ACS including both
non-Q-wave and Q-wave MI were more common
among patients without DM.
MEDICATION USE AND ADHERENCE TO DAPT. At the
time of admission, patients with DM were signiﬁ-
cantly more likely to receive aspirin, thienopyridine,
and bivalirudin. They were also more often on
long-term oral anticoagulant therapy. The use of
low–molecular weight heparin and glycoprotein
IIb/IIIa inhibitors was similar between the 2 groups
(Online Table 1). During the index PCI, proximal left
anterior descending coronary artery disease, bifur-
cation lesions, and thrombotic lesions were more
common among patients without DM. There was no
signiﬁcant difference between patients with and
those without DM in terms of number of treated
vessels, number of stents implanted, and total stent
length. Second-generation DES were preferred in
patients with DM (83.1% second generation vs.
16.9% ﬁrst generation) (Table 2). The rate of any
DAPT cessation at 30 days was similar between pa-
tients with and those without DM (2% vs. 2%;
p ¼ NS). However, at 1 and 2 years after index PCI,
patients with DM had a lower DAPT cessation rate
compared with those without DM (17.7% vs. 18.0%
at 1 year and 50.1% vs. 55.4% at 2 years; p < 0.01)
(Figure 2).
FIGURE 2 Cumulative Incidences of Dual-Antiplatelet Therapy Cessation Across the Follow-Up Time Points, Overall and by Mode
(A) The cumulative incidence of any DAPT cessation through 2 years after PCI in patients with and without diabetes mellitus. The cumulative
incidence of DAPT discontinuation, interruption, and disruption are represented in B, C, and D, respectively. DAPT ¼ dual-antiplatelet
therapy.
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When distinguishing between modes of cessation,
physician-guided discontinuation was less common
in patients with DM through 2 years (32.6% of overall
DM vs. 39.5% of all patients without DM; p < 0.001).
There was no signiﬁcant difference in either DAPT
interruption or DAPT disruption between groups,
although interruption tended to be more frequent
in patients with DM at 1 and 2 years after index PCI
(5.0% vs. 3.8% at 1 year and 11.4% vs. 9.5% at 2 years;
p ¼ 0.053) (Figure 2). Because DAPT discontinuation
emerged as the only cessation mode to differ between
the study groups, next, we investigated patterns of
DAPT discontinuation in relevant subsets of the study
population. We found no difference in the pattern
of DAPT discontinuation according to antidiabetic
treatment, oral medication or insulin (Figure 3A).
However, a subanalysis by clinical presentation
showed a lower rate of DAPT discontinuation at any
time point in patients presenting with ACS compared
with stable CAD counterparts in both patients with and
those without DM. Interestingly, the difference in the
incidence of discontinuation at 2 years between those
presenting with stable CAD and those with ACS was 3
times higher in patients with DM than in those without
DM (Figure 3B).
CLINICAL OUTCOMES. At 2 years after index PCI,
patients with DM had signiﬁcantly higher rates of
all-cause mortality (5.9% vs. 2.3%; p < 0.0001), car-
diac mortality (4.3% vs. 1.5%; p < 0.0001), probable or
deﬁnite stent thrombosis (1.7% vs. 0.9%; p ¼ 0.02),
clinically indicated target lesion revascularization
(8.5% vs. 5.6%; p < 0.001), spontaneous MI (5.0%
vs. 2.3%; p < 0.0001), and MACE (13.8% vs. 8.2%;
p < 0.0001) than patients without DM (Table 3).
Results were consistent over time at both 1 and
2 years, whereas at 30 days after index PCI, only all-
cause mortality and cardiac death were signiﬁcantly
higher among patients with DM (data not shown).
There was no difference in bleeding rates during the 2
years of follow-up according to TIMI and Bleeding
Academic Research Consortium criteria (Table 3).
FIGURE 3 Cumulative Incidences of Dual-Antiplatelet Therapy Discontinuation on the Basis of Antidiabetic Treatment and
Clinical Presentation
(A) Cumulative DAPT discontinuation rate in nondiabetics, diabetics on oral glucose lowering medications, and diabetics on insulin treatment;
(B) cumulative DAPT discontinuation rate by clinical presentation, stable CAD or ACS, in nondiabetics and diabetics. ACS ¼ acute coronary
syndrome(s); CAD ¼ coronary artery disease.
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When analyzed by antidiabetic treatment, we found
that the risk for MACE, MACE 2, cardiac death, and MI
was uniform in the diabetic population regardless of
treatment (Online Figure 1). Finally, we looked at the
time-adjusted risk for cardiovascular events across
DAPT cessation patterns compared with uninter-
rupted DAPT and observed that patients with DM had
a higher risk for all ischemic outcomes only during
disruption (MACE at disruption: HR: 2.05 [95% con-
ﬁdence interval (CI): 1.27 to 3.30]; p < 0.001; MACE 2
at disruption: HR: 2.43 [95% CI: 1.39 to 4.23];
p < 0.001; MI at disruption: HR: 3.07 [95% CI: 1.50 to
6.23]; p < 0.001) (Figure 4). Conversely, patients
without DM with DAPT disruption had only a higher
risk for MI compared with uninterrupted DAPT
(MI at disruption: HR: 3.99 [95% CI: 2.10 to 7.57];
p < 0.001), which resulted in a signiﬁcantly higher
rate of MACE 2 (HR: 2.24; 95% CI: 1.28 to 3.92;
p < 0.001). Interestingly, physician-recommended
DAPT discontinuation and interruption for #14 days
were safe in both patients with and those without DM
(MACE at interruption in patients with DM: HR: 1.75
[95% CI: 0.92 to 3.31]; p ¼ 0.08; MACE at interruption
in patients without DM: HR: 1.32 [95% CI: 0.66 to
2.64]; p ¼ 0.40). There was no interaction between
diabetic status and clinical outcomes for any cessa-
tion mode (Figure 4). When patients with DM were
subdivided by antidiabetic treatment, we observed
that disruption signiﬁcantly increased the risk for
MACE in patients with DM treated with insulin but
not with oral medication (Online Figure 2). However,
because of the limited number of adverse events in
treatment-based subgroups, these results should be
interpreted with caution.
DISCUSSION
In the present analysis involvingmore than 4,000 real-
world patients undergoing PCI predominantly with
second-generation DES, we report the following key
ﬁndings: 1) the presence of DM was associated with
increased thrombotic but not bleeding events over
2 years; 2) DAPT cessation was less frequent among
patients with DM, which was attributable primarily to
differences in rates of physician-guided discontinua-
tion between groups; 3) cardiovascular risk after
DAPT cessation because of physician-recommended
discontinuation or temporary interruption was not
increased among patients with versus without DM;
and 4) conversely, when DAPT was disrupted because
of bleeding or noncompliance, the risk for all cardio-
vascular adverse events signiﬁcantly increased in a
uniform manner irrespective of diabetic status. In
aggregate, these ﬁndings suggest that physicians
are reluctant to recommend discontinuation of anti-
platelet therapy among patients with DM, a practice
pattern that is concordant with the prothrombotic
nature of such patients. We also demonstrate that
DM is not a modiﬁer of risk subsequent to DAPT
cessation irrespective of underlying mode.
Overall, the cumulative rate of DAPT cessation
was lower among patients with DM, a ﬁnding
that was driven primarily by differences in the
rates of physician-recommended discontinuation. In
contrast, the incidence of temporary DAPT interrup-
tion did not differ signiﬁcantly between groups.
Previous studies have shown that DM is an inde-
pendent predictor of uninterrupted DAPT after PCI,
together with unstable presentation, prior MI, left
main coronary PCI, and multivessel coronary disease
(16,17). Our results extend these earlier observations
by suggesting that in a real-world context, physicians
are less likely to stop DAPT among those with DM, a
behavior that might reﬂect concerns surrounding
TABLE 3 Rate of Clinical Outcomes at 12 and 24 Months
No Diabetes
(n ¼ 2,777)
Diabetes
(n ¼ 1,430) p Value
Death
12 months 25 (0.90) 46 (3.22) <0.0001
24 months 65 (2.34) 84 (5.87) <0.0001
Cardiac death
12 months 19 (0.68) 37 (2.59) <0.0001
24 months 41 (1.48) 62 (4.34) <0.0001
Probable/deﬁnite stent thrombosis
12 months 18 (0.65) 22 (1.54) <0.01
24 months 25 (0.90) 25 (1.75) 0.02
Target lesion revascularization
12 months 109 (3.93) 77 (5.38) 0.03
24 months 157 (5.65) 121 (8.46) <0.001
Myocardial infarction
12 months 33 (1.19) 46 (3.22) <0.0001
24 months 63 (2.27) 71 (4.97) <0.0001
TIMI major
12 months 37 (1.33) 20 (1.40) 0.86
24 months 52 (1.87) 26 (1.82) 0.90
BARC major
12 months 61 (2.20) 42 (2.94) 0.14
24 months 92 (3.31) 57 (3.99) 0.26
MACE
12 months 142 (5.11) 121 (8.46) <0.0001
24 months 227 (8.17) 197 (13.78) <0.0001
MACE 2
12 months 57 (2.05) 80 (5.59) <0.0001
24 months 105 (3.78) 127 (8.88) <0.0001
Values are n (%).
BARC ¼ Bleeding Academic Research Consortium; MACE ¼ major adverse cardiac event(s)
(cardiac death, myocardial infarction, clinically indicated target lesion revascularization, or deﬁ-
nite or probable stent thrombosis); MACE 2 ¼ major adverse cardiac event(s) 2 (cardiac death,
myocardial infarction, or deﬁnite or probable stent thrombosis); TIMI ¼ Thrombolysis In
Myocardial Infarction.
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coronary thrombosis and stent thrombosis in such
patients. This practice pattern is consistent with
emerging risk algorithms highlighting the importance
of DM as an independent correlate of thrombotic, but
not bleeding, events after PCI, thereby reinforcing
the need for longer or more potent platelet inhibition
in such patients (18,19). Results from a subanalysis of
the DAPT trial, for example, suggest that prolonging
DAPT might reduce the risk for outcomes in patients
with DM, whereas the beneﬁt appears to be attenu-
ated compared with those without DM (20). In
contrast, other data from clinical trials suggest the
opposite. In a subanalysis of the OPTIMIZE (Opti-
mized Duration of Clopidogrel Therapy Following
Treatment With the Endeavor Zotarolimus-Eluting
Stent in Real-World Clinical Practice) trial, 3 months
of DAPT duration was noninferior to 12 months
in reducing the rate of net adverse clinical and
cerebral events and major cardiovascular events in a
diabetic subgroup treated with second-generation
zotarolimus-eluting stents (8). Similarly, a substudy
of the SECURITY (Second Generation Drug-Eluting
Stent Implantation Followed by Six- Versus Twelve-
Month Dual Antiplatelet Therapy) trial found no
beneﬁt in prolonging DAPT over 6 months in patients
with DM after the implantation of any second-
generation DES (21). Whether these differences
reﬂect heterogeneity in patient populations, stent
platforms, or study design remains unknown.
Although our results provide insight into clinical
decision making vis-à-vis DAPT cessation in the
setting of DM, we are unable to comment on the
optimal DAPT strategy in such patients given
the observational nature of our study design. Clearly,
additional investigation is warranted to further reﬁne
the risk/beneﬁt trade-off with different DAPT dura-
tions in patients with DM. Interestingly, we observed
no clear difference in the discontinuation pattern on
the basis of antidiabetic treatment.
In contrast to our ﬁndings with respect to
physician-guided discontinuation, we observed no
differences between groups in rates of temporary
interruption because of surgical procedures or
disruption arising from bleeding or noncompliance.
FIGURE 4 Adjusted Risk for Adverse Cardiac Events at 2 Years According to Dual-Antiplatelet Therapy Cessation Mode in Patients With
and Without Diabetes Mellitus
Patients on dual-antiplatelet therapy (DAPT) were used as the reference. All models included the following variables: age, sex, body mass
index, smoking habit, clinical presentation, region, education level, stent type, prior myocardial infarction, prior coronary artery bypass
grafting, prior percutaneous coronary intervention (PCI), thrombotic lesion, bifurcation lesion, and multivessel PCI. DM ¼ diabetes mellitus;
HR ¼ hazard ratio with 95% conﬁdence interval; MACE ¼ major adverse cardiac event(s) (cardiac death, myocardial infarction, clinically
indicated target lesion revascularization, or deﬁnite or probable stent thrombosis); MACE 2 ¼ major adverse cardiac event(s) 2 (cardiac
death, myocardial infarction, or deﬁnite or probable stent thrombosis).
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These results suggest that the presence of DM does
not play a signiﬁcant role in clinical decision making
with respect to suspension of antiplatelet therapy
when prompted by external conditions, such as
bleeding. As rates of bleeding were similar between
patients with and those without DM, the lack of any
differences in disruption is somewhat expected.
However, the comparable rates of interruption be-
tween groups may be less intuitive given the well-
established links between DM and increased platelet
reactivity, coupled with the procoagulant milieu that
characterizes the post-operative state (22,23). Several
reasons might account for the lack of a signiﬁcant
association between DM and propensity to interrupt
at time of surgery. First, most instances of interrup-
tion involved withdrawal of a single antiplatelet
agent, whereas thrombotic risk in this setting is usu-
ally related to cessation of both drugs (24). Second,
brief episodes of interruption may confer less risk in
the setting of relatively safe second-generation DES
compared with earlier stent platforms. Third, short-
term bleeding risk at the time of surgery may
outweigh comparable risks for thrombosis upon
withdrawal of antiplatelet therapy, even in the
setting of DM.
STUDY LIMITATIONS. PARIS is a prospective registry,
and all information on DAPT compliance was self-
reported and therefore subject to potential bias.
To simplify the statistical analysis, similarly to the
main PARIS study, duration of DAPT cessation (brief,
temporary, or permanent) was not taken into account
in the time-dependent multivariate regression anal-
ysis. Risk for cardiovascular outcomes for every DAPT
cessation mode was not classiﬁed according to the
drug type stopped (aspirin, P2Y12 inhibitor, or both). In
addition, in the PARIS registry only 6% of patients
were prescribed a novel P2Y12 inhibitor (prasugrel),
so comparison between different thienopyridines
cannot be performed. Because of the limited number of
events and subgroup nature of this analysis, we were
unable to examine temporal variability in risk for
adverse events associated with each DAPT cessation
mode.
CONCLUSIONS
Patients with DM present a higher cardiovascular
risk that persists for up to 2 years after index PCI.
Clinicians are less likely to recommend discontinua-
tion of DAPT among patients with DM, a behavior
that might reﬂect concerns surrounding cessation
of antiplatelet therapy in the setting of a pro-
thrombotic state. Brief episodes of DAPT interruption
or physician-recommended discontinuation were
not linked to increased risk for adverse events
among those with DM. However, disruption for poor
compliance or bleeding complications was associated
with excess cardiovascular risk irrespective of dia-
betic status.
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